<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802906</url>
  </required_header>
  <id_info>
    <org_study_id>MK-RCS-2008</org_study_id>
    <nct_id>NCT00802906</nct_id>
  </id_info>
  <brief_title>Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)</brief_title>
  <official_title>Prospective Study on the Efficacy of 1.5mg Bevacizumab Versus Selective Subthreshold Micropulslaser in Central Serous Chorioretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold
      retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection
      in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE
      to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should
      non-selectively stop the RPE leakage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the clinical efficacy of an initial subthreshold retinal
      micropulselasercoagulation in twelve eyey per group versus a single intravitreal 1.5mg
      bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively
      treat the damaged RPE to induce reproliferation of healthy RPE cells. BCVA in EDTRS score,
      OCT, and leakage in FLA, static perimetry of both groups will be correlated to a control
      group without treatment over 10 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BCVA in EDTRS values</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OCT, leakage in FA, defects in satic perimetry</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>subthreshold micropulselaser</intervention_name>
    <description>on demand if leakage is persistent or recurs after initial treatment</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>1.5 mg initial intravitreal injection</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  CSC of &gt;4 months duration

        Exclusion Criteria:

          -  History of macular or chorioretinal inflammation

          -  Lens / corneal opacities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Koss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZAU Department of Vitreoretinal surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZAU Department of VR surgery</name>
      <address>
        <city>Frankfurt / Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>September 26, 2012</last_update_submitted>
  <last_update_submitted_qc>September 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Michael Koss</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>micropulselaserphotocoagulation</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>CSC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

